Alexza
Pharmaceuticals, Inc. (Nasdaq: ALXA) announced that it has completed
the enrollment in its Phase 2a proof-of-concept clinical trial with AZ-002
(Staccato(R) alprazolam) in patients with panic disorder. AZ-002 is an
inhalation product candidate being developed for the acute treatment of
panic attacks associated with panic disorder. AZ-002 is being developed
through Symphony Allegro, a development collaboration formed between Alexza
and Symphony […]

In 2006 researchers investigating the interaction between the brain, behavior, and the immune system found that simply anticipating a mirthful laughter experience boosted health-protecting hormones. Now, two years later, the same researchers have found that the anticipation of a positive humorous laughter experience also reduces potentially detrimental stress hormones. According to Dr. Lee Berk, the […]

A paper by Giovanni A. Fava and associates of the University of Bologna published in the April issue of Psychotherapy and Psychosomatics summarizes the evidence which supports the seriousness of agoraphobia as an invalidating disease. At the same time it questions the excessive emphasis on panic which has been attributed in the past decade and […]

Individuals who experience military combat obviously endure extreme stress, and this exposure leaves many diagnosed with the psychiatric condition of post-traumatic stress disorder, or PTSD. PTSD is associated with several abnormalities in brain structure and function. However, as researcher Roger Pitman explains, "Although it is tempting to conclude that these abnormalities were caused by the […]